The National Institutes of Health (NIH) has dropped its funding for research utilizing human fetal tissue obtained from elective abortions, marking a significant shift in the agency's approach to biomedical research. This decision comes as part of an ongoing effort by the Trump administration to curtail such studies, a goal that anti-abortion advocates have been advocating for years.
Under the leadership of NIH Director Jay Bhattacharya, the agency has implemented this ban, citing its desire to modernize and advance science. According to the NIH, taxpayer-funded research must reflect the best scientific standards and values of the American people, implying a shift towards alternative methods that can model human health and disease more effectively.
The move follows in the footsteps of President Joe Biden's reversal of a policy implemented by his predecessor, Donald Trump, which had stopped funding internal research using fetal tissue from abortions. The agency has seen a decline in such projects since 2019, with only 77 funded projects worth nearly $60 million last fiscal year.
While researchers can still access fetal tissue obtained from miscarriages for certain studies, they tend to prefer using tissue from elective abortions due to the difficulties associated with collecting usable material from spontaneous miscarriages. The use of human fetal tissue has been instrumental in advancing research into various diseases, including diabetes, Alzheimer's, and infertility, as well as vaccine development for multiple illnesses.
The NIH's decision highlights the ongoing debate over the use of fetal tissue in biomedical research, a contentious issue that pits proponents who see it as a valuable tool against those who object on moral grounds.
Under the leadership of NIH Director Jay Bhattacharya, the agency has implemented this ban, citing its desire to modernize and advance science. According to the NIH, taxpayer-funded research must reflect the best scientific standards and values of the American people, implying a shift towards alternative methods that can model human health and disease more effectively.
The move follows in the footsteps of President Joe Biden's reversal of a policy implemented by his predecessor, Donald Trump, which had stopped funding internal research using fetal tissue from abortions. The agency has seen a decline in such projects since 2019, with only 77 funded projects worth nearly $60 million last fiscal year.
While researchers can still access fetal tissue obtained from miscarriages for certain studies, they tend to prefer using tissue from elective abortions due to the difficulties associated with collecting usable material from spontaneous miscarriages. The use of human fetal tissue has been instrumental in advancing research into various diseases, including diabetes, Alzheimer's, and infertility, as well as vaccine development for multiple illnesses.
The NIH's decision highlights the ongoing debate over the use of fetal tissue in biomedical research, a contentious issue that pits proponents who see it as a valuable tool against those who object on moral grounds.